HOPA 2018 Conference Banner

Session descriptions and speaker information for Saturday's sessions at HOPA's Annual Conference.

Register Now


8–9 am

Oncology Medication Utilization and Stewardship for the Health System (401) 0.1 CEUs Included in Virtual Meeting blue K

Chelsea Manion, PharmD BCOP BCPS

In 2020, the cost of cancer care is projected to hit $158 billion, and drug expenses contribute significantly to this total cost of care. In the absence of a nationally accepted value matrix and value threshold, health systems, with the support of their clinical leaders, are left to determine and define what are patient-centered, sustainable, and evidence-based oncology medication utilization practices. In doing so, we always strive to keep the cancer patient at the center of care. In this session we will review the current state of value-based oncology care in the United States, seek to understand existing financial data for some oncology medications, discuss existing value matrices and tools, and engage in conversation about feasible solutions and best practices. Although we currently have no readily defined solutions for tackling the issues of cost, consumerism, and sustainability of cutting-edge oncology practice, we must continue to consider these big-picture topics if we are to influence the course of utilization, the culture of care, and planning for sustainable, value-based practice.

8–9:15 am

Embracing the Mid-Career Crisis: Pivoting to New Career Challenges (402) 0.125 CEUs Included in Virtual Meeting blue K

David DeRemer, PharmD BCOP FCCP; Patrick Medina, PharmD BCOP; Amy Pick, PharmD BCOP; J. Michael Vozniak, PharmD BCOP

Are you experiencing a growing sense of uneasiness in your career? Are you struggling to integrate work into the busyness of life, or do you desire new career challenges? This session addresses the mid-career crises faced by many in our profession. Several HOPA members will speak about their discernment process and identify strategies they used to embrace and transition to new career opportunities. The session will conclude with a discussion on well-being and burnout, providing resources on how members can successfully integrate their career into a great life.

9–10:45 am

Research Grant Award and Platform Presentations (404) 0.175 CEUs blue K

Val Adams, PharmD; Jessica Auten, PharmD BCOP BCPS; Jill Bates, PharmD MS BCOP; Jai Patel, PharmD; Judith A. Smith, PharmD BCOP CPHQ FCCP FISOPP

This session will feature four of HOPA's Research Grant Award winners, who will share their research findings in a variety of areas.

9:30–10:45 am

Improving Writing and Speaking Skills (403) 0.125 CEUs Included in Virtual Meeting blue K

Rowena Schwartz, PharmD BCOP

There is certainly no single best way to present effectively, so this session will be an interactive discussion about strategies that the oncology pharmacist may use to optimize presenting and teaching for a range of audiences. Topics will include (1) using audiovisuals effectively, (2) modifying your presentation for your audience, (3) adapting your message during a presentation, (4) meeting continuing education criteria without compromising your individuality, and (5) using formal and informal approaches in presentations. We will also consider strategies for providing helpful feedback to presenters and ways to use feedback without losing your own style.


BCOP Session 7 (BC7) 0.125 CEUs Included in Virtual Meeting red A

Evolving Treatment Options for Newly Diagnosed and Relapsed or Refractory Multiple Myeloma: A Pharmacist’s Perspective

E. Bridget Kim, PharmD BCOP BCPS

Novel treatment options for multiple myeloma are emerging rapidly, resulting in unprecedented response rates even for relapsed or refractory disease. Optimal up-front multidrug treatment selection and subsequent therapy sequencing, however, remain unclear. This session will foster oncology pharmacists’ understanding of the various new drugs and combination regimens for multiple myeloma to aid them in making recommendations for treatment selection and sequencing. This session will also examine the pharmacist’s role in managing patients with multiple myeloma, including supportive care, specialty pharmacy services, and requirements for risk evaluation and mitigation strategies. Future advances in myeloma, including the role of personalized immunotherapy, will also be discussed.



Epigenetics: On-Off Switch (405) 0.1 CEUs Included in Virtual Meeting blue K

Joshua Pecoraro, PharmD BCOP

In this session we will review the molecular mechanisms of epigenetic drug therapy in malignancy and apply this knowledge to use of these drugs, comprehension of novel drugs in this category, and management of patients receiving these therapies. Given that most clinical successes of epigenetic drugs have occurred in the treatment of hematologic malignancies, they will be the primary focus. The intent is not to provide an exhaustive review of epigenetic drugs but to detail the mechanisms and discuss key examples to provide a framework for understanding this unique drug class. This session is intended for both new and advanced pharmacy practitioners.


All About Asparaginase (406) 0.1 CEUs Included in Virtual Meeting blue K

Joshua Elder, PharmD BCOP BCPS

Asparaginase therapy is an integral component of achieving desirable outcomes in leukemia patients. Although asparaginase therapies have been a mainstay in pediatric acute lymphoblastic leukemia protocols for quite some time, as our understanding of their importance grows, these therapies are increasingly being used in adolescent and young adult protocols. Asparaginase therapy has many intricacies with regard to efficacy and safety. This presentation will review both the benefits of asparaginase therapies on treatment outcomes and their adverse-effect profile. The management of these adverse effects, including the differentiation of anaphylactic reactions versus infusion-related reactions, will be discussed in detail. We will also discuss the appropriateness of interchanging asparaginase products. Finally, we will focus on the utility and functionality of asparaginase monitoring through a review of recent literature on the pharmacokinetics and pharmacodynamics of the available formulations and optimization of monitoring to increase efficacy. This topic is especially timely because of the lack of national standardization in this area of practice and the recent publication of consensus recommendations for how asparaginase monitoring should be carried out.

Completed Research Platform Presentations (407) 0.1 CEUs blue K

Sol Atienza, PharmD BCOP; Andrea Ledford, PharmD BCOP; Chrystia Zobniw, PharmD BCOP BCPS; Julianne Orr, PharmD; Amber Clemmons, PharmD BCOP

This session will feature four presenters discussing the findings from their recently completed research endeavors. This is a great chance to hear about groundbreaking results, especially if you weren’t able to see these posters during the Thursday reception!


Saturday, March 24–Sunday, March 25
(immediately following the HOPA 14th Annual Conference)

Fundamentals of Hematopoietic Cell Transplantation Training Course

The course, offered by the American Society for Blood and Marrow Transplantation (ASBMT), will be held Saturday, 2:30–6:05 pm, and Sunday, 7 am–1 pm, at the Colorado Convention Center. This interactive case-based course provides practitioners with the skills required to care for patients undergoing hematopoietic cell transplantation (HCT), with a focus on pharmacotherapeutic management throughout the transplant process. The target audience is pharmacists, pharmacy students and residents, physicians (including residents and hematology/oncology fellows), advanced practice providers, and nurses.

This activity is eligible for Accreditation Council for Pharmacy Education credit; see the final Continuing Pharmacy Education activity announcement for details. Additional details and registration information are available on the ASBMT website.